Dir, 10%
Ali Behbahani, M.D., M.B.A. is a Partner and Co-Head of the Healthcare team at New Enterprise Associates (NEA), a venture capital firm, where he has worked since 2007, specializing in biopharmaceuticals, medical devices, and related sectors.[[2]](https://www.spyglasspharma.com/about-us/)[[5]](https://crisprtx.com/about-us/leadership/dr-ali-behbahani)[[6]](https://www.nea.com/team/ali-behbahani-md) He serves as an Independent Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), with recent insider transactions including the conversion of NEA funds' preferred stock to common stock and the acquisition of 937,500 shares for $15 million around the company's IPO in February 2026.[[1]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-37495dc0e8a5.html)[[2]](https://www.spyglasspharma.com/about-us/)[[3]](https://www.stocktitan.net/sec-filings/SGP/form-4-spy-glass-pharma-inc-insider-trading-activity-1b4836dafe8b.html)[[9]](https://www.tipranks.com/news/insider-trading/spyglass-pharma-insiders-make-a-massive-high-stakes-bet-on-the-companys-future-insider-trading)
Behbahani holds an MD from the University of Pennsylvania School of Medicine, an MBA from The Wharton School, and bachelor’s degrees in biomedical engineering, electrical engineering, and chemistry from Duke University.[[6]](https://www.nea.com/team/ali-behbahani-md) His career highlights include prior roles at The Medicines Company, Morgan Stanley, and Lehman Brothers, research at the National Institutes of Health and Duke, and board seats at numerous biotech firms such as CRISPR Therapeutics (since 2015), Nkarta (Chairman since 2019), Arcellx, Black Diamond Therapeutics, Monte Rosa Therapeutics, and Korro Bio.[[5]](https://crisprtx.com/about-us/leadership/dr-ali-behbahani)[[6]](https://www.nea.com/team/ali-behbahani-md)[[7]](https://tunetx.com/employee/ali-behbahani/)[[8]](https://www.korrobio.com/team-member/ali-behbahani-m-d/)
View full insider profile →